{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:32:32Z","timestamp":1790332352796,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004756","name":"the Emil Aaltonen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010129","name":"the Maud Kuistila Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008723","name":"the Finnish Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008723","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Infectious Diseases Society in Finland"},{"name":"the Finnish Subsidy for Health Science Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tenofovir disoproxil fumarate (TDF), compared to tenofovir alafenamide (TAF), leads to lower body weight and plasma lipids by an unknown mechanism. We hypothesize that TDF, when absorbed, may damage enterocytes of the proximal duodenum, leading to reduced absorption of nutrients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>People with human immunodeficiency virus, without significant gastrointestinal symptoms, receiving a regimen containing TDF (n = 12) or TAF (n = 12), underwent esophagogastroduodenoscopies. Plasma\/serum concentrations of nutrients absorbed from proximal duodenum and serum intestinal fatty acid\u2013binding protein (I-FABP), a marker of enterocyte damage, were measured. Cytochrome c oxidase\/succinate dehydrogenase (COX\/SDH) staining and electron microscopy (EM) were conducted to evaluate mitochondria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Five patients in the TDF group (1 celiac disease [excluded from further analyses], 1 Helicobacter gastritis, and 3 esophagitis) and 2 in the TAF group (2 esophagitis) had a pathological finding in esophagogastroduodenoscopy. Villi were flatter (337 [59] vs 397 [42] \u03bcm; P = .016), crypts nonsignificantly deeper (200 [46] vs 176 [27] \u03bcm; P = .2), and villus-to-crypt ratio lower (1.5 [0.42] vs 2.5 [0.51]; P = .009) in the TDF versus TAF group (mean [standard deviation]). I-FABP concentration was higher in the TDF versus TAF group (3.0 [1.07] vs 1.8 [0.53] ng\/mL; P = .003). The TDF group had numerically but not statistically significantly lower concentrations of folate and vitamins A, B1, D, and E. COX\/SDH staining and EM showed similar mitochondrial damage in both groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Duodenal villous alterations may explain TDF-associated decrease in body weight and plasma lipids. Larger studies are needed to evaluate concentrations of nutrients absorbed from duodenum among TDF users..<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT05326971; EudraCT 2022-000849.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae374","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T20:13:24Z","timestamp":1721420004000},"page":"381-388","source":"Crossref","is-referenced-by-count":11,"title":["Effect of 2 Forms of Tenofovir on Duodenal Enterocytes\u2014A Hypothesis for Different Effect of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide on Body Weight and Plasma Lipids"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-8152","authenticated-orcid":false,"given":"Kai Juhani","family":"Kauppinen","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Inflammation Center, Helsinki University Hospital, Helsinki, Finland"},{"name":"Faculty of Medicine, University of Helsinki, Helksinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inka","family":"Aho","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inflammation Center, Helsinki University Hospital, Helsinki, Finland"},{"name":"Faculty of Medicine, University of Helsinki, Helksinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelli","family":"Sj\u00f6blom","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Helsinki, Helksinki, Finland"},{"name":"Department of Pathology, Helsinki University Hospital , Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Tynninen","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Helsinki, Helksinki, Finland"},{"name":"Department of Pathology, Helsinki University Hospital , Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Suomalainen","sequence":"additional","affiliation":[{"name":"Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland"},{"name":"HiLife, University of Helsinki, Helsinki, Finland"},{"name":"HUS Diagnostic Center, Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1838-7525","authenticated-orcid":false,"given":"Ursula","family":"Schwab","sequence":"additional","affiliation":[{"name":"School of Medicine, Institute of Public Health and Clinical Nutrition, University of Eastern Finland , Kuopio, Finland"},{"name":"Department of Medicine, Endocrinology and Clinical Nutrition, Kuopio University Hospital, Wellbeing Services County of North Savo , Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Helsinki, Helksinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perttu","family":"Arkkila","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Helsinki, Helksinki, Finland"},{"name":"Abdominal Center, Department of Gastroenterology, Helsinki University Hospital , Helsinki ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi","family":"Sutinen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Inflammation Center, Helsinki University Hospital, Helsinki, Finland"},{"name":"Faculty of Medicine, University of Helsinki, Helksinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"2025022409324746400_ciae374-B1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1089\/aid.2015.0147","article-title":"Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada","volume":"32","author":"Koethe","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025022409324746400_ciae374-B2","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025022409324746400_ciae374-B3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N Engl J Med"},{"key":"2025022409324746400_ciae374-B4","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/QAD.0000000000003245","article-title":"Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain","volume":"36","author":"Kauppinen","year":"2022","journal-title":"AIDS"},{"key":"2025022409324746400_ciae374-B5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer","year":"2020","journal-title":"Lancet"},{"key":"2025022409324746400_ciae374-B6","first-page":"990","article-title":"Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide in people with HIV","volume":"79","author":"Damas","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025022409324746400_ciae374-B7","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1097\/QAD.0000000000003083","article-title":"Is tenofovir disoproxil fumarate associated with weight loss?","volume":"35","author":"Shah","year":"2021","journal-title":"AIDS"},{"key":"2025022409324746400_ciae374-B8","first-page":"1006","article-title":"Which form of tenofovir should be used worldwide: tenofovir disoproxil fumarate or tenofovir alafenamide?","volume":"79","author":"Hill","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025022409324746400_ciae374-B9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/cid\/ciae191","article-title":"Antiretrovirals and weight change: weighing the evidence","volume":"79","author":"Wohl","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025022409324746400_ciae374-B10","doi-asserted-by":"crossref","first-page":"ofab542","DOI":"10.1093\/ofid\/ofab542","article-title":"Excess weight gain with integrase inhibitors and tenofovir alafenamide: what is the mechanism and does it matter?","volume":"8","author":"Wood","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025022409324746400_ciae374-B11","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/QAD.0b013e32833ad8b4","article-title":"A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206","volume":"24","author":"Tungsiripat","year":"2010","journal-title":"AIDS"},{"key":"2025022409324746400_ciae374-B12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/QAI.0000000000000940","article-title":"Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results","volume":"72","author":"Wohl","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025022409324746400_ciae374-B13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/QAD.0000000000001817","article-title":"A week-48 randomized phase-3 trial of darunavir\/cobicistat\/emtricitabine\/tenofovir alafenamide in treatment-naive HIV-1 patients","volume":"32","author":"Eron","year":"2018","journal-title":"AIDS"},{"key":"2025022409324746400_ciae374-B14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/QAD.0000000000002741","article-title":"Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa","volume":"35","author":"Chandiwana","year":"2021","journal-title":"AIDS"},{"key":"2025022409324746400_ciae374-B15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jiac.2016.08.008","article-title":"Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients","volume":"22","author":"Cheng","year":"2016","journal-title":"J Infect Chemother"},{"key":"2025022409324746400_ciae374-B16","first-page":"6069131","article-title":"Tenofovir disoproxil fumarate is associated with a set-point variation in the calcium-parathyroid hormone-vitamin D axis: results from a German cohort","volume":"2018","author":"Noe","year":"2018","journal-title":"Adv Pharmacol Sci"},{"key":"2025022409324746400_ciae374-B17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0378-5173(00)00507-X","article-title":"Species-dependent and site-specific intestinal metabolism of ester prodrugs","volume":"205","author":"Van Gelder","year":"2000","journal-title":"Int J Pharm"},{"key":"2025022409324746400_ciae374-B18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpharm.2015.03.002","article-title":"Intestinal behavior of the ester prodrug tenofovir DF in humans","volume":"485","author":"Geboers","year":"2015","journal-title":"Int J Pharm"},{"key":"2025022409324746400_ciae374-B19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/labinvest.2011.48","article-title":"Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters","volume":"91","author":"Kohler","year":"2011","journal-title":"Lab Invest"},{"key":"2025022409324746400_ciae374-B20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/ki.2010.318","article-title":"Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities","volume":"78","author":"Herlitz","year":"2010","journal-title":"Kidney Int"},{"key":"2025022409324746400_ciae374-B21","volume-title":"Advanced nutrition and human metabolism","author":"Gropper","year":"2017","edition":"7th ed"},{"key":"2025022409324746400_ciae374-B22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antiviral Res"},{"key":"2025022409324746400_ciae374-B23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/mp3002045","article-title":"Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340","volume":"10","author":"Babusis","year":"2013","journal-title":"Mol Pharm"},{"key":"2025022409324746400_ciae374-B24","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/apt.12194","article-title":"Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies","volume":"37","author":"Adriaanse","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2025022409324746400_ciae374-B25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0009-9120(03)00096-1","article-title":"Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility","volume":"36","author":"Pelsers","year":"2003","journal-title":"Clin Biochem"},{"key":"2025022409324746400_ciae374-B26","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1097\/00042737-199910000-00019","article-title":"The histopathology of coeliac disease: time for a standardized report scheme for pathologists","volume":"11","author":"Oberhuber","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025022409324746400_ciae374-B27","volume-title":"Muscle biopsy: a practical approach","author":"Dubowitz","year":"2007","edition":"3rd ed"},{"key":"2025022409324746400_ciae374-B28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/gut.52.7.960","article-title":"Seroprevalence, correlates, and characteristics of undetected coeliac disease in England","volume":"52","author":"West","year":"2003","journal-title":"Gut"},{"key":"2025022409324746400_ciae374-B29","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0016-5085(19)30511-6","article-title":"Serum lipids and fecal steroids in patients with celiac disease: effects of gluten-free diet and cholestyramine","volume":"78","author":"Vuoristo","year":"1980","journal-title":"Gastroenterology"},{"key":"2025022409324746400_ciae374-B30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000066757","article-title":"Long-term follow-up of celiac adults on gluten-free diet: prevalence and correlates of intestinal damage","volume":"66","author":"Ciacci","year":"2002","journal-title":"Digestion"},{"key":"2025022409324746400_ciae374-B31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.mayocp.2012.06.003","article-title":"Severe spruelike enteropathy associated with olmesartan","volume":"87","author":"Rubio-Tapia","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"2025022409324746400_ciae374-B32","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.5858\/arpa.2015-0204-RA","article-title":"Olmesartan-associated enteropathy: a review of clinical and histologic findings","volume":"139","author":"Choi","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"2025022409324746400_ciae374-B33","doi-asserted-by":"crossref","first-page":"1173956","DOI":"10.3389\/fimmu.2023.1173956","article-title":"Relevance of biomarkers indicating gut damage and microbial translocation in people living with HIV","volume":"14","author":"Ouyang","year":"2023","journal-title":"Front Immunol"},{"key":"2025022409324746400_ciae374-B34","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.1038\/s41467-023-43399-5","article-title":"Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01","volume":"14","author":"Huang","year":"2023","journal-title":"Nat Commun"},{"key":"2025022409324746400_ciae374-B35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2017.01.014","article-title":"Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures","volume":"140","author":"Stray","year":"2017","journal-title":"Antiviral Res"},{"key":"2025022409324746400_ciae374-B36","doi-asserted-by":"crossref","first-page":"155395","DOI":"10.1016\/j.metabol.2022.155395","article-title":"Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic signatures","volume":"141","author":"Ritou","year":"2023","journal-title":"Metabolism"},{"key":"2025022409324746400_ciae374-B37","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1136\/jcp.34.10.1181","article-title":"Measurements of intestinal villi non-specific and ulcer-associated duodenitis-correlation between area of microdissected villus and villus epithelial cell count","volume":"34","author":"Hasan","year":"1981","journal-title":"J Clin Pathol"},{"key":"2025022409324746400_ciae374-B38","first-page":"162","article-title":"Intestinal fatty acid-binding protein (I-FABP) as a new biomarker for intestinal diseases [in Japanese]","volume":"58","author":"Funaoka","year":"2010","journal-title":"Rinsho Byori"},{"key":"2025022409324746400_ciae374-B39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1089\/apc.2019.0236","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide significantly worsens the lipid profile in a real-world setting","volume":"33","author":"Kauppinen","year":"2019","journal-title":"AIDS Patient Care STDS"},{"key":"2025022409324746400_ciae374-B40","doi-asserted-by":"crossref","first-page":"e25702","DOI":"10.1002\/jia2.25702","article-title":"Weight gain before and after switch from TDF to TAF in a U.S. cohort study","volume":"24","author":"Mallon","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"2025022409324746400_ciae374-B41","first-page":"59","article-title":"Vitamin D deficiency in HIV: a shadow on long-term management?","volume":"16","author":"Orkin","year":"2014","journal-title":"AIDS Rev"},{"key":"2025022409324746400_ciae374-B42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11904-018-0401-4","article-title":"Continued interest and controversy: vitamin D in HIV","volume":"15","author":"Hsieh","year":"2018","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025022409324746400_ciae374-B43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/cid\/cir269","article-title":"Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era","volume":"53","author":"Bedimo","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025022409324746400_ciae374-B44","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/649897","article-title":"Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study","volume":"201","author":"Worm","year":"2010","journal-title":"J Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae374\/58798918\/ciae374.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/2\/381\/58798918\/ciae374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/2\/381\/58798918\/ciae374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T09:35:13Z","timestamp":1740389713000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/2\/381\/7718258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,23]]},"published-print":{"date-parts":[[2025,2,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae374","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,15]]},"published":{"date-parts":[[2024,7,23]]}}}